Headlines about Vivus (NASDAQ:VVUS) have been trending somewhat positive recently, Accern reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Vivus earned a news sentiment score of 0.22 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 46.700759118644 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the media headlines that may have effected Accern’s rankings:
A number of equities research analysts have weighed in on the stock. Zacks Investment Research lowered shares of Vivus from a “buy” rating to a “hold” rating in a report on Saturday, January 6th. ValuEngine raised shares of Vivus from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd.
VVUS traded down $0.01 during trading on Wednesday, reaching $0.38. 287,438 shares of the company’s stock were exchanged, compared to its average volume of 648,066. Vivus has a one year low of $0.33 and a one year high of $1.38. The company has a debt-to-equity ratio of -24.71, a current ratio of 6.80 and a quick ratio of 6.34. The firm has a market capitalization of $35.58, a price-to-earnings ratio of -1.31 and a beta of 0.61.
Vivus (NASDAQ:VVUS) last posted its earnings results on Tuesday, March 13th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.13) by $0.03. Vivus had a negative net margin of 46.67% and a negative return on equity of 843.43%. The firm had revenue of $11.94 million for the quarter. equities research analysts predict that Vivus will post -0.45 EPS for the current year.
TRADEMARK VIOLATION WARNING: This piece of content was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/04/vivus-vvus-earns-daily-media-impact-score-of-0-22.html.
Vivus Company Profile
VIVUS, Inc, a biopharmaceutical company, develops and commercializes therapies to address unmet medical needs in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.
Receive News & Ratings for Vivus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivus and related companies with MarketBeat.com's FREE daily email newsletter.